MADISON, New Jersey (AFX) - Wyeth Pharmaceuticals, a division of Wyeth, said it is planning in 2007 to file for a new indication for its TYGACIL drug as a treatment for patients with community-acquired pneumonia.
TYGACIL is currently indicated for the treatment of certain skin and intra-abdominal infections, it said. newsdesk@afxnews.com har COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
TYGACIL is currently indicated for the treatment of certain skin and intra-abdominal infections, it said. newsdesk@afxnews.com har COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
© 2006 AFX News
